Enhanced Virtual Trip platform goes live with improved user experience and first selection of PS2025 session videosConference ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the best get rich quick stocks to buy now. ARK Invest’s ETFs, led by Cathie Wood, ...

Market reaction to recent readouts from Compass Pathways and Beckley Psytech/atai in treatment-resistant depression speaks to ...

Research on synthetic psychedelics progresses, and there's hope to prove psilocybin safe and effective in intractable ...

This new commentary explores where psychedelic mental health treatments might be heading and what needs to happen next.

Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read why ATAI is a Buy.

Detailed price information for Atai Life Sciences N.V. (ATAI-Q) from The Globe and Mail including charting and trades.

The transaction will provide Supernus with an innovative marketed product: ZURZUVAE® (zuranolone) capsules CIV, the first and only U.S. Food and Drug Administration (FDA)-approved oral medicine ...

Detailed price information for Atai Life Sciences N.V. (ATAI-Q) from The Globe and Mail including charting and trades.

Compass Pathways has announced that its investigational psilocybin therapy, COMP360, met the primary endpoint in its Phase 3 COMP005 trial for treatment-resistant depression (TRD).